HC Wainwright Increases Aura Biosciences (NASDAQ:AURA) Price Target to $22.00

Aura Biosciences (NASDAQ:AURA) had its target price increased by HC Wainwright from $21.00 to $22.00 in a report published on Friday, Marketbeat reports. HC Wainwright currently has a buy rating on the stock.

Several other equities analysts have also weighed in on AURA. Evercore ISI raised Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. JMP Securities lifted their price objective on Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a research note on Friday, September 13th. Finally, Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $23.00.

Aura Biosciences Trading Down 0.8 %

Shares of NASDAQ:AURA opened at $11.65 on Friday. The stock’s 50-day moving average price is $8.74 and its two-hundred day moving average price is $8.10. Aura Biosciences has a 12-month low of $5.99 and a 12-month high of $12.38. The firm has a market cap of $577.18 million, a price-to-earnings ratio of -6.26 and a beta of 0.37.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.04. As a group, research analysts forecast that Aura Biosciences will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Los Pinos Elisabet De sold 24,992 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $12.04, for a total transaction of $300,903.68. Following the transaction, the insider now directly owns 329,847 shares of the company’s stock, valued at approximately $3,971,357.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Aura Biosciences news, CTO Mark Plavsic sold 7,383 shares of Aura Biosciences stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total transaction of $72,722.55. Following the sale, the chief technology officer now directly owns 121,132 shares in the company, valued at $1,193,150.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Los Pinos Elisabet De sold 24,992 shares of Aura Biosciences stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $12.04, for a total value of $300,903.68. Following the sale, the insider now owns 329,847 shares in the company, valued at $3,971,357.88. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 57,506 shares of company stock valued at $675,952. Corporate insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Aura Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Long Focus Capital Management LLC increased its holdings in Aura Biosciences by 113.4% during the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock worth $7,992,000 after purchasing an additional 561,766 shares during the last quarter. Regency Capital Management Inc. DE increased its holdings in shares of Aura Biosciences by 11.4% in the 1st quarter. Regency Capital Management Inc. DE now owns 785,136 shares of the company’s stock valued at $6,163,000 after acquiring an additional 80,162 shares during the last quarter. Levin Capital Strategies L.P. increased its holdings in shares of Aura Biosciences by 194.5% in the 2nd quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock valued at $2,476,000 after acquiring an additional 216,266 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Aura Biosciences by 20.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock valued at $1,892,000 after acquiring an additional 41,711 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Aura Biosciences by 51.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock valued at $1,081,000 after acquiring an additional 48,549 shares during the last quarter. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.